(A) Experimental scheme. (B)
Representative micrographs (scale bar: 100μm,) depicting
accumulation of internalized AF647-tagged siRNA from exosomes.
(C) Panc-1 orthotopic tumor growth. PBS: n=6 mice,
Control exos: n=6 mice, siKrasG12D iLipo: n=3
mice, shKrasG12D iLipo: n=3 mice, siKrasG12D
iExo: n=7 mice, shKrasG12D iExo: n=7 mice,
siScrbl iExo: n=5 mice, shScramble iExo: n=5 mice.
Statistical test compares treatment groups to PBS control group at day
42-post cancer cell injection, or day 28 for siKrasG12D exos
group. Unpaired two-tailed t test. This graph is an inset from the graph
shown in Fig. 2C. (D)
Tumor bioluminescence at day 77 (total flux), PBS: n=4 mice, Control
Exo: n=3 mice, shKrasG12D iExo: n=6 mice,
shKrasG12D iLipo: n=3 mice, shScramble iExo:
n=3 mice, siScramble iExo: n=4 mice. (E)
Luciferase activity at day 7, 35, 77 and moribund stage or day 200
(shKrasG12D iExo)-post cancer cell injection. Some of these
panels are also shown in Fig. 2a.
(F) Bioluminescence from Panc-1 orthotopic tumors over time
(total flux). PBS: n=7 mice, Control Exo: n=6 mice,
shKrasG12D iExo: n=7 mice, shKrasG12D
iLipo: n=4 mice, shScramble iExo: n=5 mice, siScramble iExo:
n=5 mice (G) Representative H&E of the Panc-1
orthotopic pancreas (scale bar: 100μm). (H)
Representative micrographs (scale bar: 100μm) of tumors
immunolabeled for phosphorylated AKT (p-AKT) and quantification. Control
Exo, n=4 mice; shKrasG12D iExo, n=6 mice.
Unpaired two-tailed t test. (I–J) BxPC-3 orthotopic
tumor growth, n=3 mice per group. (K) Luciferase
activity at day 14 and day 77-post cancer cell (BxPC-3) injection.
(L) Representative H&E of the BxPC-3 orthotopic
pancreas at the indicated experimental endpoints (scale bar: 100μm).
(M) Kaplan-Meier curve of BxPC-3 tumor bearing mice,
Log-rank Mantel-Cox, n=3 mice per group. The data is presented as
the mean ± SEM. Unless otherwise stated, one-way ANOVA was used to
determine statistical significance. * p<0.05, **
p< 0.01, *** p<0.001,
**** p<0.0001. See accompanying source
data.